Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline

Journal of Cardiac Failure

Volumn 16, Issue 6, 2010, Pages 475-539

  Heart Failure Society of America, ^a  

^a NONE

Author keywords

Heart failure; practice guidelines

Indexed keywords

ARTICLE; HEART FAILURE; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 77953630575     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.04.005     Document Type: Article

References (167)

1. Adams K., Baughman K., Dec W., Elkayam U., Forker A., Gheorghiade M., et al. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 5 (1999) 357-382
2. Adams K., Lindenfeld J., Arnold J., Baker D., Barnard D., Baughman K., et al. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 (2006) e1-e122
3. Hershberger R.E., Lindenfeld J., Mestroni L., Seidman C.E., Taylor M.R., and Towbin J.A. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail 15 (2009) 83-97
4. Fang J., Mensah G.A., Croft J.B., and Keenan N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52 (2008) 428-434
5. Koelling T.M., Chen R.S., Lubwama R.N., L'Italien G.J., and Eagle K.A. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 147 (2004) 74-78
6. Loehr L.R., Rosamond W.D., Chang P.P., Folsom A.R., and Chambless L.E. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 101 (2008) 1016-1022
7. McCullough P.A., Philbin E.F., Spertus J.A., Kaatz S., Sandberg K.R., and Weaver W.D. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 (2002) 60-69
8. Baker D.W. Prevention of heart failure. J Card Fail 8 (2002) 333-346
9. Dunlay S.M., Weston S.A., Jacobsen S.J., and Roger V.L. Risk factors for heart failure: a population-based case-control study. Am J Med 122 (2009) 1023-1028
10. Lee D.S., Gona P., Vasan R.S., Larson M.G., Benjamin E.J., Wang T.J., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 119 (2009) 3070-3077
11. Centers for Disease Control and Prevention. Mortality from congestive heart failure-United States, 1980-1990. JAMA 271 (1994) 813-814
12. Centers for Disease Control and Prevention. Changes in mortality from heart failure-United States, 1980-1995. JAMA 280 (1998) 874-875
13. Fox K.F., Cowie M.R., Wood D.A., Coats A.J., Gibbs J.S., Underwood S.R., et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 22 (2001) 228-236
14. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97 (1998) 1876-1887
15. Hellermann J.P., Jacobsen S.J., Reeder G.S., Lopez-Jimenez F., Weston S.A., and Roger V.L. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J 145 (2003) 742-748
16. Howard B.V. Blood pressure in 13 American Indian communities: the Strong Heart Study. Public Health Rep 111 Suppl. 2 (1996) 47-48
17. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
18. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
19. Levy D., Larson M.G., Vasan R.S., Kannel W.B., and Ho K.K. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
20. Lopes A.A., Andrade J., Noblat A.C., and Silveira M.A. Reduction in diastolic blood pressure and cardiovascular mortality in nondiabetic hypertensive patients. A reanalysis of the HOT study. Arq Bras Cardiol 77 (2001) 132-137
21. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
22. Kostis J.B., Davis B.R., Cutler J., Grimm Jr. R.H., Berge K.G., Cohen J.D., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 (1997) 212-216
23. McDonagh T.A., Morrison C.E., Lawrence A., Ford I., Tunstall-Pedoe H., McMurray J.J., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350 (1997) 829-833
24. McKee P.A., Castelli W.P., McNamara P.M., and Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
25. Mitchell G.F., Pfeffer J.M., and Pfeffer M.A. The transition to failure in the spontaneously hypertensive rat. Am J Hypertens 10 (1997) 120S-126S
26. Moser M., and Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27 (1996) 1214-1218
27. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
28. Pfeffer J.M., Pfeffer M.A., Fletcher P., Fishbein M.C., and Braunwald E. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 242 (1982) H776-H784
29. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
30. Arnold J.M., Yusuf S., Young J., Mathew J., Johnstone D., Avezum A., et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107 (2003) 1284-1290
31. Fagard R.H., and Staessen J.A. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 21 (1999) 491-497
32. Hansson L. Recent intervention trials in hypertension initiated in Sweden-HOT, CAPPP and others. Hypertension Optimal Treatment Study. Captopril Prevention Project. Clin Exp Hypertens 21 (1999) 507-515
33. Hawkins C.M. Isolated Systolic Hypertension, Morbidity, and Mortality: The SHEP Experience. Am J Geriatr Cardiol 2 (1993) 25-27
34. Lauer M.S., Anderson K.M., and Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 18 (1991) 1287-1294
35. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
36. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310 (1995) 83-88
37. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., and Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161 (2001) 996-1002
38. Djousse L., Driver J.A., and Gaziano J.M. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 302 (2009) 394-400
39. Wilson W., Taubert K.A., Gewitz M., Lockhart P.B., Baddour L.M., Levison M., et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 (2007) 1736-1754
40. Packer M., and Cohn J. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 83 (1999) 1A-38A
41. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
42. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
43. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
44. Stecker E.C., Fendrick A.M., Knight B.P., and Aaronson K.D. Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. Am Heart J 151 (2006) 820-828
45. Heidenreich P.A., Lee T.T., and Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 30 (1997) 27-34
46. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., and Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98 (1998) 1184-1191
47. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
48. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
49. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
50. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
51. Flather M.D., Shibata M.C., Coats A.J., van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
52. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
53. Deedwania P.C., Giles T.D., Klibaner M., Ghali J.K., Herlitz J., Hildebrandt P., et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149 (2005) 159-167
54. Nodari S., Metra M., Dei C.A., and Dei C.L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail 5 (2003) 803-809
55. Le Jemtel T.H., Padeletti M., and Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 49 (2007) 171-180
56. Paravastu S.C., Mendonca D., and Da S.A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev (2008) CD005508
57. Dzau V.J., Colucci W.S., Hollenberg N.K., and Williams G.H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63 (1981) 645-651
58. Okubo S., Niimura F., Nishimura H., Takemoto F., Fogo A., Matsusaka T., et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 99 (1997) 855-860
59. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 2 (1996) 47-54
60. Pitt B., Zannad F., and Remme W.J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
61. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
62. Adams Jr. K.F., Gheorghiade M., Uretsky B.F., Patterson J.H., Schwartz T.A., and Young J.B. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39 (2002) 946-953
63. Gheorghiade M., Hall V.B., Jacobsen G., Alam M., Rosman H., and Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 92 (1995) 1801-1807
64. Gheorghiade M., and Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am Heart J 134 (1997) 3-12
65. Packer M., Gheorghiade M., Young J.B., Costantini P.J., Adams K.F., Cody R.J., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329 (1993) 1-7
66. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
67. Uretsky B.F., Young J.B., Shahidi F.E., Yellen L.G., Harrison M.C., and Jolly M.K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22 (1993) 955-962
68. Young J.B., Gheorghiade M., Uretsky B.F., Patterson J.H., and Adams Jr. K.F. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol 32 (1998) 686-692
69. Yamamoto K., Ikeda U., Furuhashi K., Irokawa M., Nakayama T., and Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 25 (1995) 1634-1640
70. Sbarouni E., Bradshaw A., Andreotti F., Tuddenham E., Oakley C.M., and Cleland J.G. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 127 (1994) 607-612
71. Jafri S.M., Ozawa T., Mammen E., Levine T.B., Johnson C., and Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 14 (1993) 205-212
72. Kyrle P.A., Korninger C., Gossinger H., Glogar D., Lechner K., Niessner H., et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 54 (1985) 521-523
73. Ciaccheri M., Castelli G., Cecchi F., Nannini M., Santoro G., Troiani V., et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 62 (1989) 26-29
74. Dunkman W.B., Johnson G.R., Carson P.E., Bhat G., Farrell L., and Cohn J.N. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87 (1993) VI94-101
75. Connolly S.J., Dorian P., Roberts R.S., Gent M., Bailin S., Fain E.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 295 (2006) 165-171
76. Boyd K.J., Murray S.A., Kendall M., Worth A., Frederick B.T., and Clausen H. Living with advanced heart failure: a prospective, community based study of patients and their carers. Eur J Heart Fail 6 (2004) 585-591
77. Brostrom A., Stromberg A., Dahlstrom U., and Fridlund B. Sleep difficulties, daytime sleepiness, and health-related quality of life in patients with chronic heart failure. J Cardiovasc Nurs 19 (2004) 234-242
78. Clark J.C., and Lan V.M. Heart failure patient learning needs after hospital discharge. Appl Nurs Res 17 (2004) 150-157
79. Horowitz C.R., Rein S.B., and Leventhal H. A story of maladies, misconceptions and mishaps: effective management of heart failure. Soc Sci Med 58 (2004) 631-643
80. Martinez-Selles M., Garcia Robles J.A., Munoz R., Serrano J.A., Frades E., Dominguez M.M., et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail 6 (2004) 219-226
81. Moser D.K., and Watkins J.F. Conceptualizing self-care in heart failure: a life course model of patient characteristics. J Cardiovasc Nurs 23 (2008) 205-218
82. Rogers A.E., Addington-Hall J.M., Abery A.J., McCoy A.S., Bulpitt C., Coats A.J., et al. Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ 321 (2000) 605-607
83. Bernard S. Disease management: a pharmaceutical industry perspective. Pharmaceutical Exec 16 (1995) 48-50
84. Fonarow G.C., Stevenson L.W., Walden J.A., Livingston N.A., Steimle A.E., Hamilton M.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 30 (1997) 725-732
85. Azevedo A., Pimenta J., Dias P., Bettencourt P., Ferreira A., and Cerqueira-Gomes M. Effect of a heart failure clinic on survival and hospital readmission in patients discharged from acute hospital care. Eur J Heart Fail 4 (2002) 353-359
86. Cintron G., Bigas C., Linares E., Aranda J.M., and Hernandez E. Nurse practitioner role in a chronic congestive heart failure clinic: in-hospital time, costs, and patient satisfaction. Heart Lung 12 (1983) 237-240
87. Cline C.M., Israelsson B.Y., Willenheimer R.B., Broms K., and Erhardt L.R. Cost effective management programme for heart failure reduces hospitalisation. Heart 80 (1998) 442-446
88. Doughty R.N., Wright S.P., Pearl A., Walsh H.J., Muncaster S., Whalley G.A., et al. Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. Eur Heart J 23 (2002) 139-146
89. Ekman I., Andersson B., Ehnfors M., Matejka G., Persson B., and Fagerberg B. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J 19 (1998) 1254-1260
90. Hanumanthu S., Butler J., Chomsky D., Davis S., and Wilson J.R. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation 96 (1997) 2842-2848
91. Hershberger R.E., Ni H., Nauman D.J., Burgess D., Toy W., Wise K., et al. Prospective evaluation of an outpatient heart failure management program. J Card Fail 7 (2001) 64-74
92. Holst D.P., Kaye D., Richardson M., Krum H., Prior D., Aggarwal A., et al. Improved outcomes from a comprehensive management system for heart failure. Eur J Heart Fail 3 (2001) 619-625
93. Ledwidge M., Barry M., Cahill J., Ryan E., Maurer B., Ryder M., et al. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?. Eur J Heart Fail 5 (2003) 381-389
94. O'Connell A.M., Crawford M.H., and Abrams J. Heart failure disease management in an indigent population. Am Heart J 141 (2001) 254-258
95. Paul S. Impact of a nurse-managed heart failure clinic: a pilot study. Am J Crit Care 9 (2000) 140-146
96. Smith L.E., Fabbri S.A., Pai R., Ferry D., and Heywood J.T. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clin Cardiol 20 (1997) 949-954
97. Stromberg A., Martensson J., Fridlund B., Levin L.A., Karlsson J.E., and Dahlstrom U. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. Eur Heart J 24 (2003) 1014-1023
98. Whellan D.J., Gaulden L., Gattis W.A., Granger B., Russell S.D., Blazing M.A., et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 161 (2001) 2223-2228
99. Hebert K.A., Horswell R.L., Dy S., Key Jr. I.J., Butler M.K., Cerise F.P., et al. Mortality benefit of a comprehensive heart failure disease management program in indigent patients. Am Heart J 151 (2006) 478-483
100. Jaarsma T., van der Wal M.H., Lesman-Leegte I., Luttik M.L., Hogenhuis J., Veeger N.J., et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 168 (2008) 316-324
101. Krumholz H.M., Amatruda J., Smith G.L., Mattera J.A., Roumanis S.A., Radford M.J., et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 39 (2002) 83-89
102. Naylor M.D., Brooten D., Campbell R., Jacobsen B.S., Mezey M.D., Pauly M.V., et al. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA 281 (1999) 613-620
103. Riegel B., Carlson B., Glaser D., and Hoagland P. Which patients with heart failure respond best to multidisciplinary disease management?. J Card Fail 6 (2000) 290-299
104. Riegel B., Carlson B., Kopp Z., LePetri B., Glaser D., and Unger A. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med 162 (2002) 705-712
105. Blue L., Lang E., McMurray J.J., Davie A.P., McDonagh T.A., Murdoch D.R., et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 323 (2001) 715-718
106. Jaarsma T., Halfens R., Huijer Abu-Saad H., Dracup K., Gorgels T., van R.J., et al. Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J 20 (1999) 673-682
107. Kasper E.K., Gerstenblith G., Hefter G., Van A.E., Brinker J.A., Thiemann D.R., et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 39 (2002) 471-480
108. Kornowski R., Zeeli D., Averbuch M., Finkelstein A., Schwartz D., Moshkovitz M., et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J 129 (1995) 762-766
109. Rich M.W., Vinson J.M., Sperry J.C., Shah A.S., Spinner L.R., Chung M.K., et al. Prevention of readmission in elderly patients with congestive heart failure: results of a prospective, randomized pilot study. J Gen Intern Med 8 (1993) 585-590
110. Rich M.W., Beckham V., Wittenberg C., Leven C.E., Freedland K.E., and Carney R.M. Repetitive Hospital Admissions for Congestive Heart Failure in the Elderly. Am J Geriatr Cardiol 5 (1996) 32-36
111. Stewart S., Pearson S., and Horowitz J.D. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 158 (1998) 1067-1072
112. Stewart S., Marley J.E., and Horowitz J.D. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 354 (1999) 1077-1083
113. Stewart S., Vandenbroek A.J., Pearson S., and Horowitz J.D. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 159 (1999) 257-261
114. Stewart S., and Horowitz J.D. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation 105 (2002) 2861-2866
115. West J.A., Miller N.H., Parker K.M., Senneca D., Ghandour G., Clark M., et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 79 (1997) 58-63
116. Tilney C., Whiting S., Horrar J., Perkins B., and Vance R. Improved clinical and financial outcomes associated with a comprehensive congestive heart failure program. Disease Management 1 (1998) 175-183
117. Riegel B., Carlson B., Glaser D., Kopp Z., and Romero T.E. Standardized telephonic case management in a Hispanic heart failure population - An effective intervention. Disease Management & Health Outcomes 10 (2002) 241-249
118. Cordisco M.E., Benjaminovitz A., Hammond K., and Mancini D. Use of telemonitoring to decrease the rate of hospitalization in patients with severe congestive heart failure. Am J Cardiol 84 (1999) 860-862 A8
119. de Lusignan S., Meredith K., Wells S., Leatham E., and Johnson P. A controlled pilot study in the use of telemedicine in the community on the management of heart failure-a report of the first three months. Stud Health Technol Inform 64 (1999) 126-137
120. de Lusignan S., Wells S., Johnson P., Meredith K., and Leatham E. Compliance and effectiveness of 1 year's home telemonitoring. The report of a pilot study of patients with chronic heart failure. Eur J Heart Fail 3 (2001) 723-730
121. Heidenreich P.A., Ruggerio C.M., and Massie B.M. Effect of a home monitoring system on hospitalization and resource use for patients with heart failure. Am Heart J 138 (1999) 633-640
122. Jerant A.F., Azari R., and Nesbitt T.S. Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention. Med Care 39 (2001) 1234-1245
123. Shah N.B., Der E., Ruggerio C., Heidenreich P.A., and Massie B.M. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am Heart J 135 (1998) 373-378
124. Benatar D., Bondmass M., Ghitelman J., and Avitall B. Outcomes of chronic heart failure. Arch Intern Med 163 (2003) 347-352
125. Stewart S., MacIntyre K., Hole D.J., Capewell S., and McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3 (2001) 315-322
126. Setoguchi S., Stevenson L.W., and Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154 (2007) 260-266
127. Solomon S.D., Dobson J., Pocock S., Skali H., McMurray J.J., Granger C.B., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007) 1482-1487
128. Elkayam U., Tasissa G., Binanay C., Stevenson L.W., Gheorghiade M., Warnica J.W., et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153 (2007) 98-104
129. Stevenson L.W., Miller L.W., Desvigne-Nickens P., Ascheim D.D., Parides M.K., Renlund D.G., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110 (2004) 975-981
130. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
131. Bigger Jr. J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337 (1997) 1569-1575
132. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De M.T., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
133. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., and Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 (1999) 1882-1890
134. Buxton A.E., Lee K.L., Hafley G.E., Wyse D.G., Fisher J.D., Lehmann M.H., et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 106 (2002) 2466-2472
135. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
136. Cazeau S., Ritter P., Lazarus A., Gras D., Backdach H., Mundler O., et al. Multisite pacing for end-stage heart failure: early experience. Pacing Clin Electrophysiol 19 (1996) 1748-1757
137. Leclercq C., Cazeau S., Le B.H., Ritter P., Mabo P., Gras D., et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol 32 (1998) 1825-1831
138. Gaasch W.H. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 271 (1994) 1276-1280
139. Smith G.L., Masoudi F.A., Vaccarino V., Radford M.J., and Krumholz H.M. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41 (2003) 1510-1518
140. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
141. Pearlman E.S., Weber K.T., Janicki J.S., Pietra G.G., and Fishman A.P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 46 (1982) 158-164
142. Huysman J.A., Vliegen H.W., Van der Laarse A., and Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract 184 (1989) 577-581
143. Gwathmey J.K., Copelas L., MacKinnon R., Schoen F.J., Feldman M.D., Grossman W., et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61 (1987) 70-76
144. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105 (2002) 1503-1508
145. Adams Jr. K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
146. Blackledge H.M., Tomlinson J., and Squire I.B. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 89 (2003) 615-620
147. Krumholz H.M., Parent E.M., Tu N., Vaccarino V., Wang Y., Radford M.J., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
148. Lloyd-Jones D., Adams R., Carnethon M., De S.G., Ferguson T.B., Flegal K., et al. Heart Disease and Stroke Statistics-2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-e181
149. Felker G.M., Adams Jr. K.F., Konstam M.A., O'Connor C.M., and Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 145 (2003) S18-S25
150. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
151. Vasan R.S., Larson M.G., Leip E.P., Evans J.C., O'donnell C.J., Kannel W.B., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 (2001) 1291-1297
152. Domanski M.J., Mitchell G.F., Norman J.E., Exner D.V., Pitt B., and Pfeffer M.A. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 33 (1999) 951-958
153. Sen-Chowdhry S., Syrris P., and McKenna W.J. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 50 (2007) 1813-1821
154. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006) 1807-1816
155. Chin T.K., Perloff J.K., Williams R.G., Jue K., and Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82 (1990) 507-513
156. Kohli S.K., Pantazis A.A., Shah J.S., Adeyemi B., Jackson G., McKenna W.J., et al. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?. Eur Heart J 29 (2008) 89-95
157. Murphy R.T., Thaman R., Blanes J.G., Ward D., Sevdalis E., Papra E., et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J 26 (2005) 187-192
158. Pignatelli R.H., McMahon C.J., Dreyer W.J., Denfield S.W., Price J., Belmont J.W., et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation 108 (2003) 2672-2678
159. Sen-Chowdhry S., and McKenna W.J. Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon?. Curr Opin Cardiol 23 (2008) 171-175
160. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
161. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999) 2312-2318
162. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
163. Konstam M.A., Neaton J.D., Dickstein K., Drexler H., Komajda M., Martinez F.A., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009) 1840-1848
164. Cohn J.N., and Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 345 (2001) 1667-1675
165. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
166. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
167. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552